# ECOG-ACRIN E3311: transoral surgery followed by reduced-dose radiotherapy for HPV-positive oropharyngeal cancer

Source: https://onco.cc/key-papers/paper-e3311-transoral-surgery-ferris-jco-2022/  
OnCo record `paper-e3311-transoral-surgery-ferris-jco-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In HPV-positive oropharyngeal cancer removed by transoral robotic surgery, patients with intermediate-risk pathology did just as well with a reduced 50 Gy dose of radiotherapy as with the standard 60 Gy, supporting surgery-based de-escalation.

## Summary

Phase 2 trial of 495 patients with resectable HPV-positive oropharyngeal cancer treated with transoral surgery and neck dissection, then allocated by pathology: observation for low risk, randomisation to 50 or 60 Gy radiotherapy for intermediate risk, and chemoradiotherapy for high risk.

Two-year progression-free survival was 96.9 percent with observation, 94.9 percent with 50 Gy and 96.0 percent with 60 Gy, and 90.7 percent with chemoradiation, with better swallowing outcomes at lower doses.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2022
- DOI: 10.1200/JCO.21.01752
- Authors: Ferris RL, Flamand Y, Weinstein GS, et al.
- Findings: Two-year progression-free survival 94.9 percent with 50 Gy vs 96.0 percent with 60 Gy in intermediate-risk patients.; Low-risk patients observed after surgery had 96.9 percent two-year progression-free survival.
- What it means: Transoral surgery with pathology-guided reduced-dose radiotherapy is a validated de-escalation pathway for HPV-positive oropharyngeal cancer in experienced centres.
- Caveats: Phase 2 with no non-surgical comparator.; Requires surgical expertise with low positive-margin rates.

## Sources

- J Clin Oncol 2022: https://doi.org/10.1200/JCO.21.01752
- PubMed: https://pubmed.ncbi.nlm.nih.gov/34699271/

## Connected records

- cancers: [HPV-positive oropharyngeal cancer](https://onco.cc/cancers/hpv-positive-oropharyngeal-cancer/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-e3311-transoral-surgery-ferris-jco-2022.json